Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer

被引：14

作者：

Sullivan, Ivana ^{[1
]}

Planchard, David ^{[1
]}

机构：

[1] Inst Gustave Roussy, Med Oncol Dept, 114 Rue Edouard Vaillant, F-94805 Villejuif, France

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 07期

关键词：

alectinib; ALK-rearrangement; CNS disease; ceritinib; crizotinib; crizotinib-resistance; non-small-cell lung cancer; EML4-ALK FUSION GENE; LYMPHOMA KINASE ALK; MOLECULAR CHAPERONE HSP90; HIGH-DOSE CRIZOTINIB; BRAIN METASTASES; ACQUIRED-RESISTANCE; OLIGOPROGRESSIVE DISEASE; INHIBITOR ALECTINIB; ANTITUMOR-ACTIVITY; CONFER RESISTANCE;

D O I：

10.2217/fon.16.15

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The ALK gene plays a key role in the pathogenesis of non-small-cell lung cancer (NSCLC). Patients with NSCLC harboring an ALK-rearrangement represent the second oncogene addiction to be identified in this disease. Crizotinib was the first ALK inhibitor showing pronounced clinical activity, and is now a reference treatment for ALK-positive NSCLC disease. However, despite initial impressive responses to crizotinib, acquired resistance almost invariably develops within 12 months. The pressing need for effective second-line agents has prompted the rapid development of next-generation ALK inhibitors. These agents, notably ceritinib and alectinib as the most developed, have a higher potency against ALK than crizotinib, along with activity against tumors harboring crizotinib-resistant mutations and potentially improved CNS penetration.

引用

页码：945 / 961

页数：17

共 99 条

[91] Clinical Impact of Continued Crizotinib Administration after Isolated Central Nervous System Progression in Patients with Lung Cancer Positive for ALK Rearrangement [J].

Takeda, Masayuki ;

Okamoto, Isamu ;

Nakagawa, Kazuhiko .

JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (05) :654-657

[92] Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar [J].

Tang, Seng Chuan ;

Nguyen, Luan N. ;

Sparidans, Rolf W. ;

Wagenaar, Els ;

Beijnen, Jos H. ;

Schinkel, Alfred H. .

INTERNATIONAL JOURNAL OF CANCER, 2014, 134 (06) :1484-1494

[93] Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib [J].

Toyokawa, Gouji ;

Hirai, Fumihiko ;

Inamasu, Eiko ;

Yoshida, Tsukihisa ;

Nosaki, Kaname ;

Takenaka, Tomoyoshi ;

Yamaguchi, Masafumi ;

Seto, Takashi ;

Takenoyama, Mitsuhiro ;

Ichinose, Yukito .

JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (12) :E86-E87

[94] SIGNAL TRANSDUCTION BY RECEPTORS WITH TYROSINE KINASE-ACTIVITY [J].

ULLRICH, A ;

SCHLESSINGER, J .

CELL, 1990, 61 (02) :203-212

[95] Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non-Small-Cell Lung Cancer [J].

Weickhardt, Andrew J. ;

Scheier, Benjamin ;

Burke, Joseph Malachy ;

Gan, Gregory ;

Lu, Xian ;

Bunn, Paul A., Jr. ;

Aisner, Dara L. ;

Gaspar, Laurie E. ;

Kavanagh, Brian D. ;

Doebele, Robert C. ;

Camidge, D. Ross .

JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (12) :1807-1814

[96] The EML4-ALK Fusion Gene Is Involved in Various Histologic Types of Lung Cancers From Nonsmokers With Wild-type EGFR and KRAS [J].

Wong, Daisy Wing-Sze ;

Leung, Elaine Lai-Han ;

Kam-Ting, Kimpton ;

Tam, Issan Yee-San ;

Sihoe, Alan Dart-Loon ;

Cheng, Lik-Cheung ;

Ho, Kwok-Keung ;

Au, Joseph Siu-Kie ;

Chung, Lap-Ping ;

Wong, Maria Pik .

CANCER, 2009, 115 (08) :1723-1733

[97] Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design [J].

Woodhead, Andrew J. ;

Angove, Hayley ;

Carr, Maria G. ;

Chessari, Gianni ;

Congreve, Miles ;

Coyle, Joseph E. ;

Cosme, Jose ;

Graham, Brent ;

Day, Philip J. ;

Downham, Robert ;

Fazal, Lynsey ;

Feltell, Ruth ;

Figueroa, Eva ;

Frederickson, Martyn ;

Lewis, Jonathan ;

McMenamin, Rachel ;

Murray, Christopher W. ;

O'Brien, M. Alistair ;

Parra, Lina ;

Patel, Sahil ;

Phillips, Theresa ;

Rees, David C. ;

Rich, Sharna ;

Smith, Donna-Michelle ;

Trewartha, Gary ;

Vinkovic, Mladen ;

Williams, Brian ;

Woolford, Alison J. -A. .

JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (16) :5956-5969

[98] Targeting brain metastases in ALK-rearranged non-small-cell lung cancer [J].

Zhang, Isabella ;

Zaorsky, Nicholas G. ;

Palmer, Joshua D. ;

Mehra, Ranee ;

Lu, Bo .

LANCET ONCOLOGY, 2015, 16 (13) :E510-E521

[99] PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models [J].

Zou, Helen Y. ;

Friboulet, Luc ;

Kodack, David P. ;

Engstrom, Lars D. ;

Li, Qiuhua ;

West, Melissa ;

Tang, Ruth W. ;

Wang, Hui ;

Tsaparikos, Konstantinos ;

Wang, Jinwei ;

Timofeevski, Sergei ;

Katayama, Ryohei ;

Dinh, Dac M. ;

Lam, Hieu ;

Lam, Justine L. ;

Yamazaki, Shinji ;

Hu, Wenyue ;

Patel, Bhushankumar ;

Bezwada, Divya ;

Frias, Rosa L. ;

Lifshits, Eugene ;

Mahmood, Sidra ;

Gainor, Justin F. ;

Affolter, Timothy ;

Lappin, Patrick B. ;

Gukasyan, Hovhannes ;

Lee, Nathan ;

Deng, Shibing ;

Jain, Rakesh K. ;

Johnson, Ted W. ;

Shaw, Alice T. ;

Fantin, Valeria R. ;

Smeal, Tod .

CANCER CELL, 2015, 28 (01) :70-81

← 1 2 3 4 5 6 7 8 9 10 →